The most commonly reported side effects of ocriplasmin include visual acuity reduced, photopsia, and visual impairment, based on 695 FDA adverse event reports from 2012 to 2022.
Percentages show how often each reaction appears relative to total reports for ocriplasmin.
These are voluntary reports and do not establish that ocriplasmin caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside ocriplasmin. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
37.0% of ocriplasmin adverse event reports involve female patients and 12.5% involve male patients. The largest age group is elderly at 60%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking ocriplasmin when the adverse event was reported.
Showing 15 of 19 indications
Ocriplasmin is sold under the brand name Jetrea.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.